Estudo duplo-cego randomizado controlado por placebo de 24 semanas para avaliar a eficácia, farmacocinética e segurança de LOU064 em adolescentes (12 -
Um estudo duplo-cego, randomizado e controlado por placebo para avaliar a eficácia, a farmacocinética e a segurança do remibrutinibe (LOU064) por 24 semanas em adolescentes de 12 a menos de 18 anos de idade com urticária crônica espontânea controlada inadequadamente por anti-histamínicos H1 seguidos por uma extensão aberta opcional por até mais 3 anos e um período opcional de acompanhamento sem tratamento de segurança a longo prazo por até 3 anos adicionais
The purpose of this trial is:
- to assess the efficacy, pharmacokinetics, and safety of remibrutinib vs. placebo in adolescents from 12 to < 18 years of age suffering from chronic spontaneous urticaria inadequately controlled by H1-antihistamines
- to collect long-term efficacy, safety and tolerability data on remibrutinib in adolescents after having completed 24 weeks of treatment
- to collect safety data in this population for up to three years after the last dose of study treatment
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
This trial consists of 3 different periods:
- the "core period", which is randomized and double-blind, during which 2/3 participants will receive remibrutinib and 1/3 will receive placebo for 24 weeks. Total duration: approximately 32 weeks (10 site visits).
- an optional "open-label extension (OLE) period" proposed to all participants who completed 24 weeks of treatment of the "core period" and all scheduled assessments planned at week 24 visit . Depending on their CSU symptoms (as assessed by the doctor), participants will either receive remibrutinib for 24 weeks, or enter an observational treatment-free period for 1 year. If the CSU symptoms return during the observational period, the participants can switch to the treatment period at any time (decided by the doctor). At the end of the 24-week treatment period, if CSU is controlled, participants will enter the 1-year observational period, otherwise, they can continue with another cycle of 24-week remibrutinib treatment. The number of remibrutinib treatment or observational cycles will be limited to 6 times each. Total duration: from 1 year to approximately 3 years, and number of visits: from 3 to 15 (depending on the CSU symptoms).
- an optional "long-term treatment-free follow-up period" proposed to all participants who completed at least 4 months treatment in the "OLE period". No treatment will be given. Duration: 3 years with 1 site visit and up to 4 phone call follow-up visits.
The primary clinical question of interest is what is the effect of remibrutinib treatment versus placebo on the change from baseline in UAS7, ISS7 and HSS7 scores after 12 weeks of treatment
Tipo de estudo
Tipo de estudo
Inscrição (Real)
Inscrição
Estágio
Estágio
- Fase 3
Contactos e Locais
Locais de estudo
-
-
-
Berlin, Alemanha, 13353
- Novartis Investigative Site
-
Tübingen, Alemanha, 72076
- Novartis Investigative Site
-
-
Hesse
-
Frankfurt am Main, Hesse, Alemanha, 60590
- Novartis Investigative Site
-
-
-
-
-
CABA, Argentina, C1181ACH
- Novartis Investigative Site
-
San Miguel de Tucumán, Argentina, T4000AXL
- Novartis Investigative Site
-
-
Buenos Aires
-
CABA, Buenos Aires, Argentina, C1414AIF
- Novartis Investigative Site
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentina, S2000DEJ
- Novartis Investigative Site
-
-
-
-
Quebec
-
Montreal, Quebec, Canadá, H4A 3J1
- Novartis Investigative Site
-
-
-
-
Santiago Metropolitan
-
Santiago, Santiago Metropolitan, Chile, 8420383
- Novartis Investigative Site
-
-
-
-
-
Beijing, China, 100050
- Novartis Investigative Site
-
Beijing, China, 100069
- Novartis Investigative Site
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510091
- Novartis Investigative Site
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Novartis Investigative Site
-
-
-
-
-
Valencia, Espanha, 46014
- Novartis Investigative Site
-
-
Barcelona
-
Esplugues, Barcelona, Espanha, 08950
- Novartis Investigative Site
-
-
-
-
California
-
Bakersfield, California, Estados Unidos, 93301
- Kern Research
-
San Diego, California, Estados Unidos, 92123
- Allergy and Asthma Medical Group and Research Center
-
-
Florida
-
Miami, Florida, Estados Unidos, 33156
- Pediatric Dermatology of Miami at the Pediatric CoE
-
-
Idaho
-
Boise, Idaho, Estados Unidos, 83706
- Treasure Valley Medical Research
-
-
Illinois
-
Glenview, Illinois, Estados Unidos, 60077
- Endeavor Health
-
-
Kentucky
-
Owensboro, Kentucky, Estados Unidos, 42301
- Allergy and Asthma Specialist P S C
-
-
Ohio
-
Toledo, Ohio, Estados Unidos, 43617
- Toledo Institute of Clinical Research
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73120
- Allergy Asthma and Clinical Research
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15241
- Allergy and Clinical Immunology Associates
-
-
Texas
-
San Antonio, Texas, Estados Unidos, 78213
- RFSA Dermatology
-
-
Utah
-
Sandy City, Utah, Estados Unidos, 84093
- Allergy Associates of Utah
-
-
-
-
-
Utrecht, Holanda, 3584 CX
- Novartis Investigative Site
-
-
-
-
Hong Kong
-
Hong Kong, Hong Kong, Hong Kong, 999077
- Novartis Investigative Site
-
-
-
-
FI
-
Florence, FI, Itália, 50139
- Novartis Investigative Site
-
-
PV
-
Pavia, PV, Itália, 27100
- Novartis Investigative Site
-
-
SI
-
Siena, SI, Itália, 53100
- Novartis Investigative Site
-
-
-
-
Fukuoka
-
Kitakyushu, Fukuoka, Japão, 8078556
- Novartis Investigative Site
-
-
Kumamoto
-
Kamimashi-gun, Kumamoto, Japão, 8613106
- Novartis Investigative Site
-
-
Osaka
-
Sakai, Osaka, Japão, 5938324
- Novartis Investigative Site
-
-
Shimane
-
Izumo, Shimane, Japão, 6938501
- Novartis Investigative Site
-
-
Tokyo
-
tabashi City, Tokyo, Japão, 1738610
- Novartis Investigative Site
-
-
-
-
Sarawak
-
Kuching, Sarawak, Malásia, 93586
- Novartis Investigative Site
-
-
-
-
-
Lodz, Polônia, 90-436
- Novartis Investigative Site
-
-
-
-
-
Manchester, Reino Unido, M13 9WL
- Novartis Investigative Site
-
Southampton, Reino Unido, SO16 6YD
- Novartis Investigative Site
-
-
Cambridgeshire
-
Peterborough, Cambridgeshire, Reino Unido, PE3 9GZ
- Novartis Investigative Site
-
-
-
-
-
Bangkok, Tailândia, 10330
- Novartis Investigative Site
-
Bangkok, Tailândia, 10700
- Novartis Investigative Site
-
-
Hat Yai
-
Songkhla, Hat Yai, Tailândia, 90110
- Novartis Investigative Site
-
-
-
-
-
Adana, Turquia (Türkiye), 01330
- Novartis Investigative Site
-
-
Fatih
-
Istanbul, Fatih, Turquia (Türkiye), 34093
- Novartis Investigative Site
-
-
Sihhiye Altindag
-
Ankara, Sihhiye Altindag, Turquia (Türkiye), 06230
- Novartis Investigative Site
-
-
-
-
-
Cape Town, África do Sul, 7925
- Novartis Investigative Site
-
-
Gauteng
-
Pretoria, Gauteng, África do Sul, 0181
- Novartis Investigative Site
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Key Inclusion Criteria:
- Male and female adolescent participants aged >= 12 to < 18 years of age at the time of signing the informed consent
- CSU duration for >= 6 months prior to screening (defined as the onset of CSU determined by the investigator based on all available supporting documentation)
- Diagnosis of CSU inadequately controlled by second-generation H1-AH at the time of randomization defined as:
- The presence of itch and hives for ≥ 6 consecutive weeks prior to screening despite the use of second-generation H1-AH during this time period according to local treatment guidelines
- UAS7 score (range 0 - 42) >= 16, ISS7 score (range 0 - 21) >= 6 and HSS7 score (range 0 - 21) >= 6 during the 7 days prior to randomization (Day 1)
- Documentation of hives within three months before randomization (either at screening and/or at randomization; or documented in the participants' medical history)
Key Exclusion criteria:
- Previous use of remibrutinib or other BTK inhibitors
- Significant bleeding risk or coagulation disorders
- History of gastrointestinal bleeding
- Requirement for anti-platelet medication, except for acetylsalicylic acid up to 100 mg/d or clopidogrel up to 75 mg/d. The use of dual anti-platelet therapy (e.g., acetylsalicylic acid + clopidogrel) is prohibited
- History or current hepatic disease
- Evidence of clinically significant cardiovascular, neurological, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, hematological disorders, gastrointestinal disease or immunodeficiency that, in the investigator's opinion, would compromise the safety of the participant, interfere with the interpretation of the study results or otherwise preclude participation or protocol adherence of the participant
- History of hypersensitivity to any of the study drugs or its excipients or to drugs of similar chemical classes
- Participants having a clearly defined predominant or sole trigger of their chronic urticaria (chronic inducible urticaria) including urticaria factitia (symptomatic dermographism), cold-, heat-, solar-, pressure-, delayed pressure-, aquagenic-, cholinergic-, or contact-urticaria
- Other diseases with symptoms of urticaria or angioedema, including but not limited to urticaria vasculitis, urticaria pigmentosa, erythema multiforme, mastocytosis, hereditary angioedema, or drug-induced urticaria
- Any other skin disease associated with chronic itching that might influence in the investigator's opinion the study evaluations and results, e.g., atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus or psoriasis
Other protocol-defined inclusion/exclusion criteria may apply.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Arm 1: LOU064 (blinded)
LOU064 (blinded) taken orally b.i.d. for 24 weeks, followed by LOU064 (open-label) taken orally b.i.d. for up to 6 cycles of 24 weeks. |
LOU064 (blinded) active treatment
Outros nomes:
|
|
Comparador de Placebo: Arm 2: LOU064 placebo (blinded)
LOU064 placebo (blinded) taken orally b.i.d. for 24 weeks (randomized in a 2:1 ratio arm 1: arm 2) |
matching active drug |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change from baseline in UAS7
Prazo: Baseline, week 12
|
The Urticaria Activity Score (UAS) is sum of the Hive Severity Score (HSS) and the Itch Severity Score (ISS). UAS7 is sum of the HSS7 and the ISS7 scores. Possible range of weekly UAS7 score is 0 to 42. Complete UAS7 response is UAS7 = 0. Negative change from baseline indicates improvement. |
Baseline, week 12
|
|
Change fron baseline in ISS7
Prazo: Baseline, Week 12
|
Itch Severity Score (ISS) scale is 0 to 3. Score (ISS7) is derived by adding up average daily scores of 7 days preceding visit. Possible range of weekly score is therefore 0 to 21. Itch Severity Score scale: 0 - None 1 - Mild (minimal awareness, easily tolerated) 2 - Moderate (definite awareness, bothersome but tolerable) 3 - Severe (difficult to tolerate). Negative change from baseline indicates improvement. |
Baseline, Week 12
|
|
Change from baseline in HSS7
Prazo: Baseline, Week 12
|
Hives Severity Score (HSS) scale is 0 to 3. A weekly score (HSS7) is derived by adding up the average daily scores of the 7 days preceding the visit. Possible range of the weekly score is therefore 0 to 21. Hives Severity Score scale: 0 - None 1 - Mild (1-6 hives/12 hours) 2 - Moderate (7-12 hives/12 hours) 3 - Severe (>12 hives/12 hours). Negative change from baseline indicates improvement. |
Baseline, Week 12
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Cmax of remibrutinib
Prazo: At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake
|
The maximum (peak) observed blood drug concentration after single dose administration |
At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake
|
|
Tmax of remibrutinib
Prazo: At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake
|
The time to reach maximum (peak) blood drug concentration after single dose administration |
At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake
|
|
AUClast of remibrutinib
Prazo: At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake
|
The Area Under the Curve (AUC) from pre-dose to the last measurable concentration sampling time |
At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake
|
|
Absolute change from baseline in ISS7
Prazo: Baseline - Week 12
|
Itch Severity Score (ISS) scale is 0 to 3. Score (ISS7) is derived by adding up average daily scores of 7 days preceding visit. Possible range of weekly score is therefore 0 to 21. Itch Severity Score scale: 0 - None 1 - Mild (minimal awareness, easily tolerated) 2 - Moderate (definite awareness, bothersome but tolerable) 3 - Severe (difficult to tolerate). Negative change from baseline indicates improvement. |
Baseline - Week 12
|
|
Absolute change from baseline in HSS7
Prazo: Baseline - Week 12
|
Hives Severity Score (HSS) scale is 0 to 3. A weekly score (HSS7) is derived by adding up the average daily scores of the 7 days preceding the visit. Possible range of the weekly score is therefore 0 to 21. Hives Severity Score scale: 0 - None 1 - Mild (1-6 hives/12 hours) 2 - Moderate (7-12 hives/12 hours) 3 - Severe (>12 hives/12 hours). Negative change from baseline indicates improvement. |
Baseline - Week 12
|
|
Achievement of UAS7 ≤ 6 (yes/no)
Prazo: Week 12 and over time
|
Disease activity control is defined as UAS7 ≤ 6. The Urticaria Activity Score (UAS) is sum of the Hive Severity Score (HSS) and the Itch Severity Score (ISS). UAS7 is sum of the HSS7 and the ISS7 scores. Possible range of weekly UAS7 score is 0 to 42. |
Week 12 and over time
|
|
Achievement of UAS7 = 0 (yes/no)
Prazo: Week 12 and over time
|
Complete absence of hives and itch is defined as UAS7 = 0. The Urticaria Activity Score (UAS) is sum of the Hive Severity Score (HSS) and the Itch Severity Score (ISS). UAS7 is sum of the HSS7 and the ISS7 scores. Possible range of weekly UAS7 score is 0 to 42. |
Week 12 and over time
|
|
Absolute change from baseline in CDLQI score
Prazo: Week 12
|
The Children Dermatology life Quality Index (CDLQI) score range is 0 to 30, with 0 (meaning no impact of skin disease on quality of life) to 30 (meaning maximum impact on quality of life). |
Week 12
|
|
Number of weeks without angioedema, assessed by the cumulative number of weeks with an AAS7 = 0 response
Prazo: baseline - Week 12
|
Angioedema Activity Score (AAS7) is a measure of the frequency and intensity of angioedema episodes. The total possible range of scores over 7 days is 0-105 where higher scores indicate increased angioedema activity. |
baseline - Week 12
|
|
Occurrence of treatment-emergent adverse events (AE) and serious adverse events (SAE) during the core period
Prazo: 28 weeks
|
To demonstrate the safety and tolerability of remibrutinib by assessing occurrence of treatment emergent adverse events and serious adverse events during the core period of the study. |
28 weeks
|
|
Occurrence of treatment emergent AEs, and SAEs during the Open Label Extension (OLE) period
Prazo: 3 years
|
To demonstrate the safety and tolerability of remibrutinib by assessing occurrence of treatment emergent adverse events and serious adverse events during the OLE period of the study. |
3 years
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Diretor de estudo: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Processos Patológicos
- Doença crônica
- Atributos da doença
- Doenças do sistema imunológico
- Hipersensibilidade, Imediata
- Hipersensibilidade
- Doenças de pele
- Urticária
- Doenças de Pele, Vasculares
- Condições Patológicas, Sinais e Sintomas
- Doenças da Pele e do Tecido Conjuntivo
- Urticária Crônica
- RUNIBRUTINIB
Outros números de identificação do estudo
Outros números de identificação do estudo
- CLOU064F12301
- 2022-502159-78-00 (Outro identificador: EU CT Number)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .